Home
General
Agenda
Lodging
Abstract Submission
Program Committee
Registration
Contact
CME Activity
Agenda

April 26

8:00 a.m. - 8:15 a.m. Poster Set Up (Day 1 Posters)
8:15 a.m. - 8:30 a.m. Welcome and Plenary Introduction
Robert Yarchoan
Office of HIV and AIDS Malignancy
National Cancer Institute, NIH, USA
8:30 a.m. - 9:00 a.m. HPV Vaccination in HIV-Positive Men and Women- Challenges and Opportunities
Joel Palefsky
University of California, San Francisco, USA
9:00 a.m. - 10:30 a.m. Session 1: Cervical Cancer Control in Developing Countries
Moderators: Joe Harford
National Cancer Institute, NIH, USA

Joel Palefsky
University of California, San Francisco, USA

9:00 a.m. - 9:30 a.m. Cervical Cancer Control in Developing Countries: Impact of HIV Infection
Rengaswamy Sankaranarayanan
International Agency for Research on Cancer, France
9:30 a.m. - 10:00 a.m. A Population-Based Study of Point-of-Care HPV Testing, Visual Inspection with Acetic Acid, and Cervical Cytology in Rwandan Women of Known HIV-Serostatus
Eugene Mutimura
Women's Equity in Access to Care and Treatment, Rwanda
9:45 a.m. - 10:00 a.m. CIRDZ/UAB Cervical Cancer Prevention Program in Zambia
Groesbeck P. Parham
University of Alabama, USA
10:00 a.m. - 10:30 a.m. Factors Impacting Introduction of HPV Vaccination in Low Resource Settings
Aisha Jumaan, PATH, USA
10:15 a.m. - 10:30 a.m. Questions and answers (directed at all speakers)
10:30 a.m. - 11:00 a.m. Break: Coffee and Poster Viewing
11:00 a.m. - 12:30 p.m. Session 2: KSHV Biology

Moderators: Denise Whitby
NCI-Frederick, USA

Dirk Dittmer
University of North Carolina at Chapel Hill, USA

11:00 a.m. - 11:30 a.m. B cellInfection by KSHV and its Control by T Cells
Don Ganem
University of California, San Francisco, USA
11:30 a.m. - 11:45 a.m. Bim nuclear translocation and inactivation by HHV-8 interferon regulatory factor 1
John Nicholas
Johns Hopkins University School of Medicine, USA
11:45 a.m. - 12 noon Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
Utthara Nayar
Weill Cornell Medical College, USA
12 noon - 12:15 p.m. Upregulation Angiopoietin-like 4 by viral G Protein-coupled Receptor Promotes Angiogenesis and Vascular Permeability in Kaposi's sarcoma
Silvia Montaner
University of Maryland, USA
12:15 p.m. - 12:30 p.m. KSHV regulation of fibulins in Kaposi's sarcoma: Implications for tumorigenesis
Donald Alcendor
Meharry Medical College, USA
12:30 p.m. - 1:00 p.m. Lunch (lunch on your own) or pre-bought lunch box
1:00 p.m. - 2:00 p.m. Poster Viewing (Presenters stand by posters)
2:00 p.m. - 3:30 p.m. Session 3: New and Old Viruses-Impact on Chronic Diseases
Moderators:C. David Pauza
Institute of Human Virology

Kishor Bhatia
National Cancer Institute, NIH, USA

2:00 p.m. - 2:30 p.m. Pathogenic Consequences of Xenotropic Murine Virus-related Virus (XMRV) Expression in the Development of Chronic Diseases
Frank Ruscetti
National Cancer Institute, NIH, USA
2:30 p.m. - 3:00 p.m. Merkel Cell Polyomavirus and Two Novel Polyomaviruses Are Chronically Shed from Human Skin
Christoper Buck
National Cancer Institute, NIH, USA
3:00 p.m. - 3:15 p.m. HIV-associated Salivary Gland Disease: A Role for BK Virus
Liesl K. Jeffers
University of North Carolina at Chapel Hill, USA
3:15 p.m. - 3:30 p.m. Bacteria mediated reactivation of Gammaherpesviruses
Jennifer Webster-Cyriaque
University of North Carolina at Chapel Hill, USA
3:30 p.m. - 5:30 p.m. Break: Coffee and Poster Viewing
4:00 p.m. - 5:15 p.m. Session 4: Clinical Trials Data in HIV/AIDS-Associated Malignancies
Moderators: Alexandra Levine
City of Hope National Medical Center, USA

Richard Little
National Cancer Institute, NIH, USA

4:00 p.m. - 4:15 p.m. Phase II AIDS Malignancy Consortium (AMC) trial of Imatinib in AIDS-associated Kaposi's sarcoma (KS)
Henry B. Koon
Case Western Reserve University, USA
4:15 p.m. - 4:30 p.m. Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-associated Herpes Virus (KSHV) associated Multicentric Castleman Disease (MCD)
Thomas Uldrick
National Cancer Institute, NIH, USA
4:30 p.m. - 4:45 p.m. The KAART Trial: A randomised controlled trial of HAART compared to the combination of HAART and chemotherapy in treatment naïve patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa
Thomas Uldrick
National Cancer Institute, NIH, USA
4:45 p.m. - 5:00 p.m. Distinct Profiles of Antibodies to Kaposi Sarcoma-Associated Herpesvirus Antigens in Patients with Kaposi Sarcoma, Multicentric Castlemen's Disease, and Primary Effusion Lymphoma
Peter D. Burbelo
National Institute of Dental and Craniofacial Research, NIH, USA
5:00 p.m. - 5:15 p.m. Pooled analysis of aids-malignancy consorTium (AMC) trials evaluating rituximab plus either chop or infusional epoch chemotherapy in Hiv-associated Non-Hodgkin's lymphoma
Stefan K. Barta
Montefiore-Einstein Cancer Center, USA
5:15 p.m. End of Day One

April 27

8:00 a.m. - 8:15 a.m. Poster Set Up (Day 2 Posters)
8:15 a.m. - 8:25 a.m. Opening Comments
Geraldina Dominguez
National Cancer Institute, NIH, USA
8:25 a.m. - 8:30 a.m. Plenary Introduction
Eric Engels
National Cancer Institute, NIH, USA
8:30 a.m. - 9:00 a.m. Epidemiology of HIV-Associated Cancers: New Findings from the Long-Term Follow-Up of Cohorts on HAART
Gary Clifford
International Agency for Research on Cancer, France
9:00 a.m. - 10:00 a.m. Session 5: Epidemiology of HPV-Associated Cancers
Moderators: John Brooks
Centers for Disease Control and Prevention

Eric Engels
National Cancer Institute, NIH, USA

9:00 a.m. - 9:15 a.m. Cervical cancer epidemiology among HIV-infected women in North America
Gypsyamber D'Souza
Johns Hopkins Bloomberg School of Public Health, USA
9:15 a.m.- - 9:30 a.m.  Progression of Cervical Neoplasia in HIV Seropositive Women with and without Antiretroviral Therapy in Johannesburg, South Africa
Cynthia Firnhaber
University of Witwatersrand, Johannesburg, South Africa
9:30 a.m. - 9:45 a.m. Persistence of anal squamous intraepithelial lesions and anal HPV infection in HIV-infected patients despite immune restoration under cART
Christophe Piketty
Hôpital Européen Georges Pompidou, Paris, France
9:45 a.m. - 10:00 a.m. Risk of anal cancer in HIV-Infected patients and HIV-uninfected controls in North America
Michael J. Silverberg
Kaiser Permanente Northern California, USA
10:00 a.m. - 10:30 a.m. Break: Coffee and Poster Viewing
10:30 a.m. - 11:00 a.m. Plenary Introduction
Sam Mbulaiteye
National Cancer Institute, NIH, USA

HIV and Cancer among Children in Africa
Robert Newton
University of York, United Kingdom

11:00 a.m. - 12 noon Session 6: International Partnerships
Moderators: Corey Casper
Fred Hutchinson Cancer Research Center, USA

Sam Mbulaiteye
National Cancer Institute, NIH, USA

11:00 a.m. - 11:15 a.m. Integrative proteomics and genomics supports a role for interferon gamma in the pathogenesis of Kaposi Sarcoma and finds multiple candidate diagnostic proteins for early detection or prevention
Lynn Amon
Fred Hutchinson Cancer Research Center, USA
11:15 a.m. - 11:30 a.m. Malignant lymphoma incidence and HIV-related lymphoma subtypes in the Western Cape of South Africa, 2002-2009
Leona Ayers
Ohio State University, USA
11:30 a.m. - 11:45 a.m. HPV Genotype and EGFR Activation in Conjunctival Carcinoma Among HIV Patients in East Africa
Scot C. Remick
West Virginia University, USA
11:45 a.m. - 12 noon Visual inspection and HPV-based cervical cancer screening for HIV-infected women in Pune, India
Vikrant Sahasrabuddhe
Vanderbilt University, USA
12 noon - 12:30 p.m. Lunch (lunch on your own) or pre-bought lunch box
12:30 p.m. - 1:30 p.m. Poster Viewing (Presenters stand by posters)
1:30 p.m. - 3:00 p.m. Session 7: EBV Biology and Lymphomagenesis
Moderators: Elliot Kieff
Harvard Medical School, USA

Ethel Cesarman
Weill Cornell Medical College, USA

1:30 p.m. - 2:00 p.m. Epigenetic and Transcriptional Programming and Therapy in B-Cell Lymphomas
Ari Melnick
Weill Cornell Medical College, USA
2:00 p.m. - 2:15 p.m. An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells
Mica Luftig
Duke University School of Medicine, USA
2:15 p.m. - 2:30 p.m. TNFAIP3(A20) genetic alterations in AIDS related lymphomas
Lisa Giulino
New York Presbyterian Hospital, Well Cornell Medical College, USA
2:30 p.m. - 2:45 p.m. C/EBPbeta mediates bortezomib-induced EBV and KSHV lytic gene expression
Courtney O'Farrell
Johns Hopkins School of Medicine, USA
2:45 p.m. - 3:00 p.m. Elevated serum levels of CXCL13 precede HIV-associated non Hodgkin's lymphoma
Shehnaz K. Hussain
University of California, Los Angeles, USA
3:00 p.m. - 3:30 p.m. Break: Coffee and Poster Viewing
3:30 p.m. - 4:45 p.m. Session 8: Cancers in the Era of Combination Antiretroviral Therapy
Moderators: Richard Ambinder
Johns Hopkins School of Medicine, USA

Joseph Sparano
Albert Einstein College of Medicine, USA

3:30 p.m. 3:45 p.m. Decreased risk of breast cancer associated with X4-tropic HIV
Nancy A. Hessol
University of California, San Francisco, USA
3:45 p.m. - 4:00 p.m. HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence, outcome and evolution of CD4+ T cell lymphocytes
Matthias Egger
Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland
4:00 p.m. - 4:15 p.m. Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy
Emilie Lanoy
INSERM, Paris, France